Skip to main content
. 2022 Jan 14;13(2):2028–2043. doi: 10.1080/21655979.2021.2019872

Figure 2.

Figure 2.

ADIRF-AS1 knockdown restricts the malignancy of OS cells. (a) The interference efficiency of si-ADIRF-AS1#1 and si-ADIRF-AS1#2 in OS cells was validated by qRT-PCR. (b) Effects of ADIRF-AS1 deficiency on OS cell proliferation. (c) The apoptosis of OS cells treated with si-ADIRF-AS1 was examined by flow cytometric analysis. (d, e) The migratory and invasive properties of OS cells transfected with si-ADIRF-AS1 or si-NC. **P < 0.01.